SSKN Strata Skin Sciences

STRATA Skin Sciences Expects Record Full Year 2022 Revenue

STRATA Skin Sciences Expects Record Full Year 2022 Revenue

  • Unaudited, preliminary revenue within the range of $35-$36 million
  • Record revenue represents approximately 17-19% growth over full year 2021

HORSHAM, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced record, preliminary revenue for the full year 2022 in the range of $35-$36 million, which is at the upper-end of previously announced guidance ($33-$35 million) and compares to $30 million reported for the full year 2021.

“Last year proved to be a record year for STRATA with preliminary full year revenue in the range of $35-$36 million, representing approximately 17-19% growth over the full year 2021,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences. “This past year the team remained focused on growing the top-line through driving XTRAC® usage, refurbishing and redeploying underutilized devices, and focusing on international sales. We are excited by these positive results and look forward to continuing this momentum throughout 2023.”

The preliminary, unaudited results described in this press release are estimates and are subject to revision until the company reports its full financial results for the year ended December 2022, which is anticipated in March 2023.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing and marketing innovative products for the in-office treatment of various dermatologic conditions such as psoriasis, vitiligo, and acne. Its products include the XTRAC® and Pharos® excimer lasers, VTRAC® lamp systems, and now the TheraClear®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell an acne treatment device and to integrate that device into its product offerings, the Company’s ability to develop, launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to dermatologist marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions or supply chain interruptions resulting from the coronavirus and political factors or conditions affecting the Company and the medical device industry in general, future responses to and effects of COVID-19 pandemic and its variants including the distribution and effectiveness of the COVID-19 vaccines, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at and .



Investor Contact:

Rich Cockrell

CG Capital

Phone: +1 (404) 736-3838



EN
01/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Strata Skin Sciences

 PRESS RELEASE

STRATA Skin Sciences Confirms Nasdaq Delisting

STRATA Skin Sciences Confirms Nasdaq Delisting HORSHAM, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that a Form 25 has been filed today with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and confirms that trading of the Company’s common stock has been suspended from trading on The Nasd...

 PRESS RELEASE

Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and A...

Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser Latest STRATA customer strengthens academic leadership in XTRAC excimer laser treatment for psoriasis, vitiligo, and atopic dermatitis HORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today announces that Johns Hopkins Dermatology has added the XTRAC® 308 nm excimer laser to its clinical treatme...

 PRESS RELEASE

STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Effi...

STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis Growing body of clinical data like February 2026 publication from Georgetown University supports optimized, targeted Excimer laser UVB strategies for inflammatory skin conditions HORSHAM, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today highlights findings from a February 2026 systematic review and meta-analysis...

 PRESS RELEASE

STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 20...

STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) November 19-22, 2025, where it presented its XTRAC® excimer laser and TheraclearX® acne therapy system. STRATA also reported that, by the end of 2025, there will be over 12 new recurring TheraclearX® accounts in Mexico, reflecting gro...

Strata Skin Sciences Inc: 1 director

A director at Strata Skin Sciences Inc sold/bought 19,094 shares at 1.334USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch